Rausch S, Gaisa N, Youssef R F, Lotan Y, Stenzl A, Kälble T
Urologische Universitätsklinik Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Deutschland,
Urologe A. 2014 Mar;53(3):368, 370-4. doi: 10.1007/s00120-013-3406-z.
Squamous cell carcinoma (SCC) and transitional carcinoma with squamous differentiation (SCC/TCC) are rare in western countries. Chronic inflammation and irritation of the urothelium are common risk factors for the development of SCC and TCC/SCC. Tumour biology of squamous cell cancer and precancerous squamous lesions is different from transitional cell cancer (TCC). Recent advances in molecular analysis of benign and malignant squamous cell lesions indicate that they are closely associated and might lead to improved bladder cancer subclassification in the future.
At present, the clinical management and therapy of SCC remains challenging, as scientific evidence based on prospective clinical trials is not available. We performed an analysis of available literature on natural history, treatment, and prognosis of SCC, SCC/TCC and metaplastic lesions. Furthermore, recent findings in molecular cancer biology are discussed with a focus on their relevance for SCC carcinogenesis.
在西方国家,鳞状细胞癌(SCC)和伴有鳞状分化的移行细胞癌(SCC/TCC)较为罕见。尿路上皮的慢性炎症和刺激是SCC以及TCC/SCC发生发展的常见危险因素。鳞状细胞癌和癌前鳞状病变的肿瘤生物学与移行细胞癌(TCC)不同。对良性和恶性鳞状细胞病变的分子分析的最新进展表明,它们密切相关,可能会在未来改进膀胱癌的分类。
目前,SCC的临床管理和治疗仍然具有挑战性,因为缺乏基于前瞻性临床试验的科学证据。我们对有关SCC、SCC/TCC和化生病变的自然史、治疗及预后的现有文献进行了分析。此外,还讨论了分子癌症生物学的最新发现,重点是它们与SCC致癌作用的相关性。